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such as the National Health Service, from the United Kingdom. 
Severe CSA-AKI is independently associated with 3-8-fold higher 
mortality, increased expenses, and lengthy ICU stays.
Due to the lack of a uniform definition of AKI, research into 
its detection and management strategies has been having 
difficulties in comparing the outcomes. The most frequently 
used classifications by researchers are Risk, Injury, Failure, Loss 
of kidney function, and End-stage kidney disease (RIFLE), Acute 
Kidney Injury Network (AKIN), and Kidney Disease Improving 
Global Outcomes (KDIGO). RIFLE and AKIN use criteria such 
as change in serum creatinine (SCr) level, increase of at least 
1.5 times from the baseline, and urine output of < 0.5ml/kg/h 
for at least six hours[5]. KDIGO is based on the combination of 
RIFLE and AKIN criteria and has become a novel consensus 
classification for diagnosis of CSA-AKI; it has also been shown to 
have greater sensitivity in detection of AKI postoperatively than 
other classifications[6].
Currently, AKI is diagnosed based mainly on sharp rises in SCr 
levels, however this can take up to 48 hours to raise and become 
clinically significant and, therefore, it is not an effective method 
of detecting AKI; hence, novel biomarkers are needed to allow 
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Abstract
Objective: To comprehensively understand cardiac surgery-
associated acute kidney injury (CSA-AKI) and methods of prevention 
of such complication in cardiac surgery patients.
Methods: A comprehensive literature search was performed 
using the electronic database to identify articles describing acute 
kidney injury (AKI) in patients that undergone cardiac surgery. There 
was neither time limit nor language limit on the search. The results 
were narratively summarized.
Results: All the relevant articles have been extracted; results have 
been summarized in each related section. CSA-AKI is a serious post-
operative complication and it can contribute to a significant increase 
in perioperative morbidity and mortality rates. Optimization of 
factors that can reduce CSA-AKI, therefore, contributes to a better 
postoperative outcome.
Conclusion: Several factors can significantly increase the rate 
of AKI; identification and minimization of such factors can lead 
to lower rates of CSA-AKI and lower perioperative morbidity and 
mortality rates. 
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INTRODUCTION
Acute kidney injury (AKI) is a condition that is characterized 
by a sudden deterioration of kidney function as indicated by 
a reduced glomerular filtration rate (GFR)[1]. Cardiac surgery-
associated acute kidney injury (CSA-AKI) originates from 
cardiac surgery and percutaneous coronary interventions with 
prolonged intensive care stays leading to either renal injury and/
or high mortality rates postoperatively; cardiac surgery is also 
the second most common cause of AKI in the intensive care unit 
(ICU)[1]. Nephrotoxins, metabolic abnormalities, ischemia and 
reperfusion injury, pre-existing chronic diseases, inflammation, 
and oxidative stress all contribute to the development of AKI 
postoperatively[2].
Depending on different classifications, the incidence of AKI 
post cardiac surgery varies from 5 to 43%, with 1 to 7% of them 
requiring dialysis[3]. The large variation in the incidence rate is 
dependent on the type of the surgical procedure performed, 
ranging from as high as 94% in heart transplantation to as low 
as 3% in thoracic surgery[3]. In addition, up to 52% of children 
are being diagnosed with AKI post cardiac surgery[4], which can 
create huge socioeconomic burdens on clinical institutions 
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AKI following cardiac surgery. Firstly, advancing age is associated with 
declining renal function and an associated reduction in estimated 
GFR, which compromises normal renal physiology and increases 
predisposition to developing AKI postoperatively. Secondly, studies 
have found an increased tendency for females to develop AKI 
compared with males[8]. Lastly, another study has reported better 
morbidity and mortality outcomes following development of 
postoperative AKI in Afro-Caribbean races, compared with their 
Caucasian counterparts[9].
For patients undergoing cardiac surgery, baseline comorbidities 
and functional status are two extremely important factors, which 
can determine the likelihood of developing AKI postoperatively. 
Patients with comorbidities, such as chronic obstructive pulmonary 
disease, diabetes mellitus, congestive cardiac failure, and pre-
existing chronic kidney disease (CKD), are all likely to be predisposed 
to developing renal insult following cardiac procedures. This 
could be due to impaired renal perfusion, endothelial insult, 
and decreased renal reserve. Furthermore, patients with such 
comorbidities are frequently administered a variety of nephrotoxic 
medications, such as nonsteroidal anti-inflammatory drugs 
(NSAIDs), angiotensin-converting enzyme inhibitors (ACEIs), and 
angiotensin receptor blockers (ARBs), all of which further adversely 
alter glomerular perfusion and may induce nephropathy. Hence, 
this leads to increased likelihood of impaired renal function and 
higher susceptibility towards developing AKI postoperatively.
Preoperative cardiac insult is another factor that has been 
associated with the development of postoperative AKI. Mao 
This review focuses on the pathophysiology, risk factors, 
diagnosis, management, and prevention of CSA-AKI.
PATHOPHYSIOLOGY AND RISK FACTORS
The precise pathophysiology of CSA-AKI remains not 
completely understood. However, animal and human studies 
suggested that the mechanisms appear to be multifactorial, with 
each of these factors interacting with one another preoperatively, 
intraoperatively, and postoperatively. These include genetic 
predisposition, nephrotoxins, cardiopulmonary bypass (CPB)-
induced haemolysis, ischemic-reperfusion injury, complexity of 
cardiac surgery, oxidative stress, and inflammation (Figure 1)[7].
Furthermore, CSA-AKI is a serious postoperative complication, 
which can lengthen recovery in up to 30% of patients and is the 
strongest predictor of mortality following surgery[7]. A complex 
interplay between patient and procedure-related factors can be 
attributed to the development of AKI postoperatively. Patients 
undergoing cardiac surgery are particularly susceptible due to 
the unique physiology and underlying procedures involved, 
including aortic cross-clamping (ACx) and CPB and the use of 
frequent transfusions and vasopressor[7]. Figure 1 highlights the 
pathophysiological mechanisms leading to development of AKI.
Preoperative Risk Factors
Patients’ demographics including advancing age, race, and 
gender are all non-modifiable preoperative risk factors for developing 
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et al.[1] describes the risk associated with low cardiac output in 
either the pre, intra, or postoperative period and the increased 
likelihood of developing postoperative AKI due to reduced 
perfusion pressures and global renal ischaemic insult. This can 
be attributed to sympathetic hyperactivity and the simultaneous 
activation of the renin-angiotensin-aldosterone system, which 
leads to renal vasoconstriction and, hence, reduced renal 
perfusion[1]. Low cardiac output and insult may also warrant 
the use of preoperative intra-aortic balloon pump, which has 
also been associated with development of postoperative AKI, as 
suggested by Rosner et al.[8]
Recently, genetic predisposition to AKI has been studied. 
Stafford Smith et al. conducted an unbiased genome-wide 
associated study which identified two new loci, namely 
rs13317787 in GRM7|LMCD1-AS1 intergenic region (3p21.6) 
and rs10262995 in BBS9 (7p14.3), that increased the risk of AKI 
following coronary artery bypass grafting (CABG)[10]. The authors 
also speculated that their findings may become a predictive tool 
to improve individualised AKI risk stratification in cardiac surgery 
patients. According to a genetic polymorphisms study, the 
apolipoprotein E, a cardinal protein for lipoprotein metabolism, 
tissue repair, and immunomodulation, was associated with AKI, 
and the only genotype that possessed AKI protective effect was 
the ε4 allele[11].
Patients undergoing cardiac surgery often have had 
reduced renal blood flow due to recent myocardial infarction 
or valvular disease with reduced cardiac output. Administration 
of nephrotoxic medications, such as loop diuretics, NSAIDs, 
ACEIs, ARBs, and antibiotics (e.g. aminoglycoside or beta-lactam 
inhibitors), prior to or after surgery could further enhance the 
likelihood of developing AKI. The use of antibiotics can lead to 
acute interstitial nephritis or direct injury whereas ACEIs and 
Fig. 1 – Pathophysiology of cardiac surgery-associated acute kidney injury. ACEIs=angiotensin-converting enzyme inhibitors; 
ARBs=angiotensin receptor blockers; NSAIDs=nonsteroidal anti-inflammatory drugs
Table 1. Preoperative risk factors associated with 
development of acute kidney injury.
Race




   Peripheral vascular disease
   Chronic obstructive pulmonary disease
   Congestive cardiac failure
   Pre-existing renal disease
   Diabetes
   Anemia
   Chronic liver disease
   Previous cerebrovascular accidents
Generalized atherosclerotic disease
Preoperative use of intra-aortic balloon pump
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damage caused by iron has been thought to contribute to AKI 
development. Obialo et al.[14] have also suggested that ACx and 
aortic de-clamping during CPB can also result in subsequent 
ischaemia and contribute to reperfusion injury along with 
systemic embolization. The use of CPB circuit is associated 
with haemodilution due to CPB machines being primed with a 
minimum of 1.5-2 L non-hematic crystalloid/colloid fluids. This 
results in a reduction of hematocrit concentrations of about < 
20%, which causes a reduction in the oxygen-carrying capacity 
of blood and, hence, ischaemia to end organs.
Lastly, the role of pulsatile versus non-pulsatile flow has been 
discussed as a contributory factor to AKI postoperatively. Mao 
et al.[1] have also demonstrated that off-pump cardiac surgery 
offers more physiological renal perfusion, decreases the systemic 
inflammatory response, and causes less systemic embolization, 
which are common complications associated with on-pump 
cardiac surgery. Pulsatile flow was developed to increase the 
mechanical energy transmitted via CPB circuit, which results 
in increased release of vasodilatory substances, less systemic 
vascular resistance, and improved end-organ perfusion[1]. 
However, this remains a controversial risk factor as there is no 
definitive evidence base that suggests that off-pump surgery is 
more beneficial compared with on-pump surgery.
C. Inflammation
The conventional CPB on-pump CABG provokes systemic 
inflammation response and has been associated with elevated 
postoperative plasma concentration of pro-inflammatory 
cytokines compared with off-pump coronary artery bypass 
(OPCAB), leading to increased mortality. A systematic review 
by Cheungpasitporn et al.[15], which included 33 randomised 
controlled trials (RCTs), demonstrated a protective effect of OPCAB 
in lowering AKI risk, but the finding was contraindicated by the 
largest multicenter RCT (the CORONARY trial)[16], which found no 
significant difference between the OPCAB and on-pump CABG 
groups. In conclusion, the use of OPCAB in reducing incidence of 
AKI still remains unclear in the current reported literature.
The mechanisms of increased inflammatory response are 
not well defined, but the complement activation during CPB 
is believed to occur mainly through the alternative pathway 
when the blood is in contact with the surface of extracorporeal 
circuits[17]. In a prospective study, Bruins et al. reported a biphasic 
complement activation in cardiac surgery patients, which 
activated not only during CPB but also during the first five days 
thereafter, that increased C-reactive protein levels, contributing 
to the second activation[17].
Other stimuli, such as endotoxemia, tissue injury, operative 
trauma, and pre-existing left ventricular dysfunction, could 
possibly play a role in activation of the immune system. Pro-
inflammatory cytokines and free radicals are produced, leading to 
renal tubular injury, which is further enhanced by the activation 
of neutrophils, macrophages, and migration of lymphocyte to 
renal parenchyma[18]. Ischemia-reperfusion injury occurs and 
induces the production of reactive oxygen species (ROS). The 
ROS, in turn, activate the up-regulation of pro-inflammatory 
transcription factors, including nuclear factor kappa B, 
ARBs can cause volume depletion and inhibition of renal efferent 
arteriolar vasoconstriction, respectively[7]. Multiple studies have 
demonstrated a directly causal relationship between the use 
of intravenous radiocontrast for diagnosis (angiography or 
ventriculography) and the development of contrast-induced 
nephropathy (CIN). This is affected by several factors, including 
type and dose of contrast medium, and patients’ demographics, 
such as age, gender, hydration status, and underlying 
comorbidities, including CKD[12].
Another potential nephrotoxin is free haemoglobin resulting 
from CPB-induced haemolysis. CPB haemolyzes erythrocytes 
and leads to the generation of intravascular free haemoglobin, 
which depletes circulating haptoglobin and directly injures renal 
endothelium and tubular epithelium through iron-facilitated 
free radical oxidation[1].
Another common cause of CSA-AKI is renal atheroembolism. 
Preoperative procedures, such as cardiac catheterization, aortic and 
left atrial manipulation, aorta cannulation, and ACx, could lead to 
deposition of emboli in renal artery, further exacerbating ischaemia 
and triggering inflammatory response. Other factors that could play 
a role in the reduction of renal blood flow leading to diminished 
glomerular filtration rate include increased sensitivity to sympathetic 
nervous system, activation of renin-angiotensin-aldosterone 
cascade, and circulating vasopressin or catecholamines[7]. Table 1 
highlights the frequently associated preoperative risk factors with 
the development of AKI post cardiac surgery.
Intraoperative Risk Factors
O’Neal et al.[7] suggest that ACx, CPB, and the frequent use 
of blood transfusions and vasopressors are unique to cardiac 
surgery. However, such factors have repeatedly been reported to 
increase the risk of developing AKI following such operations[13].
A. Ischemic Injury or Inadequate Renal Perfusion and Reperfusion
Even though the kidneys receive approximately a quarter 
of the cardiac output, the renal blood flow to the medulla is 
low compared to the cortex where the glomerular filtration 
and reabsorption of solute occurs normally. The shunting of 
blood from arterial to venous vasa recta results in the deficiency 
of oxygen in the high metabolic demands region, the outer 
medulla, which corresponds to the thick ascending limb of 
the loop of Henle. This region is responsible for the generation 
of osmotic gradient by active reabsorption of sodium, which 
requires high oxygen consumption. In addition, the medullary 
partial pressure of oxygen is lower than that of the cortex, 10 
to 20 mm Hg and around 50 mm Hg, respectively. Hence, renal 
medulla and corticomedullary junction are more vulnerable 
to hypoxic and ischemic damages when there is any factor in 
cardiac surgery that affects the renal perfusion.
B. Cardiopulmonary Bypass
CPB exposes red blood cells to artificial surfaces within the 
CPB circuit causing their haemolysis[8]. The breakdown of these 
cells results in haemoglobin deposition within the intratubular 
vasculature of the kidneys. This combined with the oxidative 
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inflammatory mediators, and adhesion molecules, leading to 
cellular injury and AKI[8]. Table 2 demonstrates intraoperative risk 
factors that can influence the development of postoperative AKI.
Postoperative Risk Factors
Postoperatively, predominant factors influencing the 
development of AKI include haemodynamic instability, 
nephrotoxic, inotropic and vasoconstrictor drugs, and systemic 
inflammation[8]. The presence of congestive heart failure or left 
ventricular dysfunction postoperatively are significant factors 
contributing to development of AKI due to the impaired ejection 
fraction and perfusion pressure to the kidneys[7]. Moreover, pre-
existing anaemia or the development of anaemia following 
surgery can also results in AKI due to the reduced oxygen-
carrying capacity of red blood cells and ischaemic insult to the 
renal system. Table 3 is a summary of key postoperative factors 
contributing to the development of AKI post cardiac surgery.
Khan et al. studied the role of packed red blood cell (PRBC) 
blood transfusion in causing CSA-AKI in 1210 adult patients 
undergoing cardiac surgery. The study demonstrated that 
blood transfusion of at least two units is associated with AKI, 
which caused doubling of SCr from the preoperative value 
and doubling of postoperative urinary novel biomarkers, such 
as interleukin-18 (IL-18) and neutrophil gelatinase-associated 
lipocalin (NGAL). However, the authors acknowledged that the 
study was limited by its observational nature, no set transfusion 
trigger, and variable age of PRBC; also, a direct potential causal 
association between PRBC and AKI could not be confirmed[19].
BIOMARKERS IN THE SETTING OF AKI
In the clinical practice, SCr remains the diagnostic standard 
of AKI. According to KDIGO classification, if SCr increases by ≥ 
0.3 mg/dl (26.5 μmol/l) within 48 hours, SCr is 50% higher than 
the baseline within first seven days, or urine output is below 
0.5 ml/kg/hour for six hours, the patient is considered to have 
AKI[20]. However, the classic markers (SCr, urea, and urine output) 
are insensitive and nonspecific to renal injury. SCr often leads to 
delaying of diagnosing AKI as it can only be detected 48 to 72 
hours after cardiac surgery, when glomerular filtration is already 
substantially reduced. SCr is not considered a robust marker for 
timely diagnosis in AKI and does not provide enough time for 
therapeutic treatment to work as it is subjected to several non-
renal factors, such as gender, age, fluid therapies, drugs, muscle 
metabolism, medical conditions, and other circumstances[19].
Since SCr has various limitations, scientists have discovered 
the theoretical advantage of a panel of novel serum and urinary 
biomarkers that may closely reflect the early detection, even 
without the concurrent renal dysfunction, and prognostication 
of CSA-AKI. NGAL, the most extensively studied substance, is 
reported as an early biomarker of AKI after CPB, which increases 25-
fold within two hours and declines six hours after CPB[21]. Urinary 
IL-18, a pro-inflammatory cytokine, raised at four to six hours after 
cardiac surgery, peaked at over 25-fold at 12 hours and remained 
significantly elevated up to 48 hours after surgery[21]. NGAL and 
IL-18 could be early predictors of important outcomes such as 
length of hospitalisation, need for dialysis, and mortality[21].
In 2014, the United States Food and Drug Administration 
(FDA) has approved the production of tissue inhibitor of 
metalloproteinases-2 (TIMP2) and insulin-like growth factor 
binding protein 7 (IGFBP7) markers, involved in growth phase 
cell-cycle arrest of tubular epithelial cells, for their usefulness in 
the early detection of moderate to severe AKI defined as KDIGO 
stages 2 and 3. The product of both markers can be detected as 
early as four hours after surgery, and a decline in these markers 
was the strongest predictor of renal recovery[22]. TIMP2 and 
IGFBP7 can be a bedside test as they are easily measured by Point 
of Care kit (NephroCheck) approved by FDA[22].
Serum cystatin C (CyC) is a low molecular weight protease 
inhibitor that is rapidly filtered by glomerulus. CyC reflects 
changes in GFR as the level increases when GFR decreases. CyC 
has also been found to have a better predictive value of AKI 
when compared with the conventional markers as it detects AKI 
two days earlier than creatinine[23].
Other promising urine proteins, such as kidney injury 
molecule-1 (KIM-1) and liver fatty-acid binding protein (L-FABP), 
Table 2. Intraoperative risk factors associated with 
development of acute kidney injury.
Increased cardiopulmonary bypass time
Type of procedure:
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have been commonly introduced and investigated in animal 
models and preliminary human studies[21]. In adults, KIM-1 
peaked two days after surgery, whereas L-FABP peaked within six 
hours after surgery[21]. KIM-1 could be helpful in differentiating 
ischemic AKI from prerenal azotemia and CKD.
However, the superiority of one biomarker over another and 
the cost effectiveness of using new biomarkers remain unclear. 
Given the multifactorial pathophysiology of CSA-AKI, clinicians 
could use the clinical assessment of patients with combination 
of these novel AKI biomarkers as a part of a panel for early 
prediction of AKI. Table 4 is a summary of the key biomarkers.
PREVENTION OF AKI
Preoperative Prevention Strategies
A. Renal Recovery to Prevent Contrast-Induced AKI
The use of contrast agents frequently in clinical procedures 
prior to cardiac surgery is known to be nephrotoxic and also 
to promote development of contrast-induced AKI (CI-AKI), 
depending on factors such as type and dose of contrast agent, 
underlying CKD, age, and hydration status. Intravenous isotonic 
crystalloid solutions could decrease CI-AKI risk; however, excessive 
hydration using this medium may increase the incidence of 
CI-AKI. Cardiac surgery should be delayed whenever possible 
to prevent increased risk of AKI and to allow renal recovery as 
suggested by Medalion et al.[24]
B. Avoidance of Intraoperative Anaemia and Haemolysis
Low preoperative and intraoperative haemoglobin levels 
are associated with AKI post cardiac surgery. Karkouti et al.[25] 
reported that the risk of AKI is independent of the lowest 
haemoglobin values but it is significantly increased when 
haemoglobin decreases more than 50% below baseline. 
An association between low perioperative haemoglobin 
concentrations and postoperative AKI in non-cardiac surgeries 
exists[26], and may well apply for cardiac surgeries as well. This 
indicates that preoperative haemoglobin levels should be 
optimised preoperatively.
C. Choice of Surgery Technique
In a systematic review of 33 RCTs with 17322 patients, the 
authors reported a pooled risk ratio (RR) of AKI in the off-pump 
vs. on-pump CABG groups to be 0.87 (95% confidence interval 
[CI], 0.77-0.98)[27]. However, off-pump CABG may not have any 
effect on death, stroke, and myocardial infarction as concluded 
by Lamy et al.[16]. On the other hand, Reents et al.[27] have found 
no significant difference in the incidence of AKI. Conflicting 
results provide unclear evidence to the superiority of off-pump 
CABG in reduction of AKI rate.
Intraoperative Prevention Strategies
A. Glucose Homeostasis
Hyperglycaemia is associated with increased incidence of 
AKI, mortality, and morbidity[28]. Van den Berghe et al.[28] first 
investigated the effects of glucose homeostasis and found out 
that intensive insulin therapy (blood glucose level of 80-110 
mg/dL) relative to conventional control (180-200 mg/dL) was 
associated with decreased morbidity and mortality. However, 
subsequent studies have failed to produce similar results[29]. Song 
et al.[29] did demonstrate an association between intraoperative 
glucose concentration > 150 mg/dl and AKI risk after OPCAB; 
however, they have failed to reaffirm the significance of intensive 
insulin therapy (< 110 mg/dL) on AKI. KDIGO recommends that 
blood glucose levels should not exceed 150 mg/dL, but that 
insulin therapy should not be used to lower blood glucose to 
less than 110 mg/dL.
B. Goal-Directed Therapy (GDT)
GDT is associated with a reduction in the incidence of AKI, 
renal replacement therapy (RRT), ICU stay, and hospital stay, 
as well as decreased risk of renal dysfunction and reduced 
mortality[30]. Magruder et al.[31] investigated the effects of goal-
directed perfusion therapy on AKI in a pilot study where AKI 
incidence was 23.9% in control patients vs. 9.1% in the GDT 
group, indicating an association between reduced AKI and GDT.
C. Epidural Anaesthesia
Thoracic epidural analgesia (TEA) leads to a significantly 
decreased risk of AKI development post CABG surgery[32]. 
However, Svircevic et al.[33] produced conflicting results 
suggesting the risk of TEA usage in a patient who may require 
full heparinisation. Nonetheless, the use of epidural analgesia 
in cardiac surgery has been associated with a reduction in 
mortality[34].
D. Remote Ischaemic Preconditioning
Remote ischaemic preconditioning (RIPC) has been 
hypothesised to prevent organ dysfunction in cardiac surgery 
patients; however, the use of RIPC as a preventative measure is 
still controversial. RIPC has failed to show significant reduction of 
the incidence of AKI after cardiac surgery[35].However, Zarbock et 
al.[36] have found out that RIPC significantly reduced the 3-month 
incidence of mortality, need for RRT, and renal injury in high-risk 
patients undergoing cardiac surgery. Available evidence makes it 
unclear whether RIPC is effective against AKI.
E. Fluid Management
The type of fluid administered may affect the rate of 
development of AKI. Martin et al.[37] found crystalloids to be 
less efficient at stabilising resuscitation endpoints than colloids. 
Within crystalloid solutions, isotonic saline administration is 
associated with increased AKI risk due to excess chloride. Buffered 
crystalloid fluid therapy produces no difference in the risk of AKI 
when compared to saline solution[38]. However, a systematic 
review of 6253 patients proposed that postoperative fluid 
resuscitation with balanced crystalloids reduced incidence of AKI 
when compared to physiologic saline solutions[39]. Hydroxyethyl 
starch has been associated with an increased risk of AKI; hence, it 
should be considered carefully in high-risk patients[40,41]. Table 5 
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Table 4. Novel biomarkers for prediction of CSA-AKI.
Biomarker Description Advantages Disadvantages
Soluble urokinase plasminogen 
activator receptor (suPAR) 
Serum biomarker detected 
in body fluids like blood, 
urine, peritoneal fluids, and 
cerebrospinal fluids
- Preoperative detection of 
AKI - suPAR is a more sensitive 
detector than serum creatinine 
as suPAR levels are elevated in 
AKI patients when creatinine 
levels are not
- A reliable cutoff value for suPAR 
levels was not determined
Neutrophil gelatinase-
associated lipocalin (NGAL) 
NGAL is an iron-transporting 
glycoprotein which gathers in 
the kidney tubules and urine 
after nephrotoxic and ischemic 
insult
- Levels increase rapidly after 
renal ischemia-reperfusion injury
- Renoprotective role in 
regeneration of kidney tubule
- Influenced by non-renal 
factors such as age, anaemia, 
cancer, CKD, and inflammatory 
conditions
- Urine sample difficult to obtain 
in patients with severe oliguria
Interleukin-18
24kDa precursor, produced 
by various tissues such as 
monocytes, macrophages, and 
proximal tubular epithelial cells
- Biomarker with risk stratification 
potential, assist with stratification 
of patients based on severity of 
AKI
- Mediator of ischemic 
reperfusion injury
- Urine sample difficult to obtain 
in patients with severe oliguria




lectin, which is a regulator of 
inflammation and tissue fibrosis
- Preoperative detection of AKI - Associated with renal fibrosis
Tissue inhibitor of 
metalloproteinases-2 (TIMP2) 
and insulin-like growth factor 
binding protein 7 (IGFBP7) 
Soluble protein expressed by 
kidney involved in cell-cycle 
arrest during earliest phases of 
cellular stress and tubular injury
- Risk stratification of patients 
into high and low risk can 
be done, it is a better risk 
stratification than standard 
clinical assessment
- Oliguria impedes urine 
sampling of TIMP2 and IGFBP7
- There is an association between 
elevated CCABs and diabetes 
which might reflect subclinical, 
subacute, or chronic diabetes-
associated renal injury and 
create a major cofounder to the 
predictive value for CSA-AKI




expressed in tubular kidney 
injury to help in removal of 
necrotic and apoptotic debris
- Urinary KIM-1 increased rapidly 
in models of ischemic AKI
- Influenced by non-renal 
factors such as sepsis, contrast 
media, age, diabetes mellitus, 
hypertension, and atherosclerosis
- Role in carcinogenesis of renal 
cell carcinoma
Netrin-1
Small protein which plays an 
important role in formation of 
new blood vessels, cell adhesion, 
and tumorigenesis
- Protective role in promotion of 
kidney epithelial cell proliferation 
and inhibition of apoptosis
- High in patients with ischemia, 
contrast agents, drugs, and 
sepsis, hence, association with 
AKI might not be independent
Growth-differentiation 
factor-15
Expressed in many organs 
such as heart, lung, liver, and 
intestines, and is an independent 
predictor of postoperative renal 
dysfunction
- Preoperative detection
- Superior predictive ability 
compared to risk scores such as 
EuroSCORE
- Marker is also associated with 
mortality and morbidity, hence, 
association with AKI might not 
independent
AKI=acute kidney injury; CCABs=cell-cycle arrest biomarkers; CKD=chronic kidney disease; CSA-AKI=cardiac surgery-associated 
acute kidney injury
218
Brazilian Journal of Cardiovascular Surgery 
Braz J Cardiovasc Surg 2020;35(2):211-24Harky A, et al. - Kidney Injury Post Cardiac Surgery
is a summary of the key studies comparing both solution types.
Perioperative fluid overload is also associated with increased 
severity of AKI and increased mortality post cardiac surgery[42]. 
In a recent study by Bhaskaran et al.[43], they found out that 
perioperative use of chloride-restricted intravenous fluids is 
associated with statistically significant lower incidence of AKI stage 
I, whilst chloride-liberal intravenous fluids are associated with 
hypochloremia acidosis and increased incidence of AKI stage I post 
CABG. Hence, continued chloride-restricted fluids could possibly 
reduce incidence of AKI and result in better clinical outcomes.
Positive fluid balance management is strongly associated 
with a higher AKI rate; however, there is no association between 
volume of negative fluid balance and AKI incidence[44].
Table 5. Crystalloid and colloid solutions in prevention of AKI.
Study Objective Definition Intervention Results Conclusion
Myburgh et al[40]. 
To investigate the 
efficacy of hydroxyethyl 
starch (HES) for fluid 
resuscitation and effects 
on renal function.
RIFLE
6% HES in 0.9% 
saline vs. 0.9% 
saline solutions 
until discharge, 
death, or 90-day 
randomisation.
AKI incidence: 34.6% 
in HES group vs. 38% 
in saline group. Renal 
replacement therapy 
(RRT) incidence: 7.0% 
in HES group vs. 5.8% 
in saline group.
HES provided no 
clinical benefit and 
resulted in increased 
rate of RRT.
Haase et al.[68]
To evaluate the 
efficacy of prophylactic 
bicarbonate-based 
infusion to reduce the 





(5.1 mmol/mL) vs. 
saline solution started 
before surgery until 
24 hours after the 
end of procedure.
AKI incidence: 
47.7% in sodium 
bicarbonate group 




was 6.3% vs. 1.7% in 
control group
Greater mortality 
and no prophylactic 














(0.5 mmol kg-1 for 1 
h upon induction of 
anaesthesia followed 
by 0.15 mmol kg-1 
h-1 for 23 h) vs. 0.9% 
saline.
Incidence of AKI: 21% 
in bicarbonate group 
vs. 26% in control 
group. More patients 
required prolonged 
mechanical 
ventilation (> 24 h) 
relative to the control 
group.
Perioperative use of 
sodium bicarbonate 
did not reduce 
incidence of AKI and 
might be associated 
with a needed for 
prolonged ventilatory 
care.
Young et al[38]. 
To investigate the effect 
of buffered crystalloid 
compared with saline on 
renal complications in 




crossover trial in 4 
ICUs. Participants 
were assigned 
Plasma-Lyte 148 or 
saline solution for 
alternating treatment 
blocks of 7 weeks 
over 28 weeks.
9.6% developed AKI 
within 90 days in 
buffered crystalloid 
group vs. to 9.2% in 
saline group.
Use of crystalloid 
fluid therapy was 
ineffective in 
prevention of AKI in 
the ICU.
AKI=acute kidney injury; AKIN=Acute Kidney Injury Network; ICU=intensive care unit; RIFLE=Risk, Injury, Failure, Loss of kidney 
function, and End-stage kidney disease
F. Miniaturized CPB
Initially, the miniaturized cardiopulmonary bypass (MCPB) 
systems have been developed to render on-pump cardiac 
surgeries more efficient and the preliminary reported incidence 
of AKI was lower in patients that had MCPB than those with 
conventional CPB (29% vs. 41%)[45]. However, in the study by Chew 
et al.[46], they have identified similar rates of AKI in both cohorts 
and thus the superiority of either technique remains debatable[46].
G. Duration of CPB
Several studies have found out that there is a potential 
direct association between prolonged CPB and ACx times and 
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Additionally, it is important to optimise haemodynamics in 
the pre, intra, and postoperative periods. This includes reducing 
preload, increasing afterload, and improving the contractility 
of the heart to increase the cardiovascular efficacy during 
surgery. There is ongoing debate as to the use of colloids vs. 
crystalloids in doing so; Meersche et al. recommend the use of 
crystalloid solutions with balanced electrolytes to mimic normal 
homeostatic physiology as closely as possible whilst tightly 
regulating blood pressure[13]. This prevents renal ischaemia 
and ensures adequate perfusion throughout, preventing renal 
tubular and parenchymal injuries. On the other hand, studies 
have also suggested that the use of colloids is the best strategy 
to maintain intravascular volume and haemodynamic stability. 
Paradoxically, studies also advise fluid restricting patients, as 
Stewart et al. have previously demonstrated a reduction in ICU 
stay and more ventilator-free days in cardiac surgery patients 
who underwent conservative fluid management[49].
B. Renal Replacement Therapy
For patients with severe AKI or oliguric renal failure, RRT is 
the only effective therapeutic intervention; this includes the 
use haemodialysis, haemofiltration, or haemodifiltration[13]. 
The indications for RRT have been extensively studied, yet no 
definitive evidence has been established regarding the most 
appropriate criteria or timing to initiate or discontinue RRT. Sun 
et al. have demonstrated a correlation between the initiation of 
early RRT and reduced mortality, improved survival rates, and 
an overall reduction in ICU length of stay[50]. Furthermore, early 
intervention also reduces risk of hyperkalaemia, uraemia, and 
acidaemia, whilst also providing haemodynamic stability.
1. Indications for RRT
Some of the urgent indications to initiate RRT include 
azotemia, oliguria, and pulmonary oedema, with or without 
peripheral oedema that is unresponsive to diuretic therapy[51]. 
Moreover, Palevsky et al.[52] also suggested the presence of 
severe hyperkalaemia, acid-base imbalances, encephalopathy, 
and uraemic pericarditis to be significant pathologies that 
should direct use RRT[52].
2. RRT Failure Risk Factors
Older age, intra and postoperative blood transfusions, non-
emergent surgery, gender, and increased preoperative SCr and 
uric acid levels have all been attributed as risk factors for failure 
to respond to RRT[53]. RRT also exposes patients to a variety of 
risks, including the possibility of developing encephalopathy, 
aspiration, coagulopathies, such as bleeding disorders and 
plate dysfunction, and bacteraemia. However, these risks are 
outweighed by the benefits of achieving haemodynamic stability 
with use of RRT and potential improvement in renal function.
PHARMACOLOGICAL PROTECTION
Several pharmacological approaches to prevent CSA-AKI 
have been studied and published, but, at present, there is no 
clear evidence to support the use of any pharmacological drug 
development of AKI. Karim et al.[47] reported a positive association 
between increasing ACx and CPB times and incidence of CSA-
AKI; they found out that CPB time > 70 min increased the risk of 
CSA-AKI by an odds ratio (OR) of 4.76 when compared to CPB 
time > 140 min with an OR of 6.30. In a meta-analysis of nine 
studies by Kumar et al.[47], they concluded that longer CPB and 
ACx times are strongly associated with higher incidence of AKI; 
however, they were unable to determine the safe cutoff time. 
Nevertheless, the consensus is that the shorter the CPB or ACx 
time, the less likely development of CSA-AKI.
H. Haemoadsorption Device
This technique uses a cytokine adsorber to eliminate 
inflammatory mediators, i.e., cytokines to restore immune 
homeostasis. Since inflammation is associated with the 
development of CSA-AKI, haemoadsorption, mediating this 
response, can potentially reduce the risk of AKI. Studies have 
reported that the haemoadsorption device used in cardiac 
surgeries involving CPB leads to cytokine reduction, improves 
haemodynamic stability and organ function[48], and reduces 
postoperative systemic inflammatory response syndrome (SIRS).
MANAGEMENT OF AKI
A. Conservative Management
Following development of AKI post cardiac surgery, 
management options include conservative treatment focused 
on using pharmacological interventions or the use of RRT.
Prevention of AKI development following cardiac surgery 
remains the optimal management; this includes optimization 
of multiple factors in the pre, intra, and postoperative periods. 
Rosner MH et al.[8] recommended identification of high-
risk patients preoperatively using comorbidities and the 
abovementioned scoring systems. Several measures have been 
demonstrated to be useful, such as withholding nephrotoxic 
medications like ACEI, ARBs, and NSAIDs to prevent hypotension 
during bypass, as well as metformin to prevent lactic acidosis.
Intraoperative measures should aim to improve renal reserve 
by improving perfusion pressures and, hence, reducing ischaemic 
insult to the kidneys, especially in those patients who are known 
to have pre-existing CKD. For patients with a background of 
CKD requiring dialysis, they can undergo dialysis 24 hours pre 
and postoperatively. Moreover, intraoperative hemofiltration 
plays a role in decreasing systemic fluid overload and improving 
respiratory function in patients with background congestive 
heart failure. KDIGO have also highlighted the importance of 
strict glycaemic control as well as avoidance of contrast agents 
in high-risk patients.
Loop diuretics can be used if oliguric renal failure persists 
despite optimisation of the abovementioned factors. This 
intervention can often convert oliguric to non-oliguric renal 
failure, preventing tubular damage, decreasing oxygen 
consumption, and potentially improving urine output[8]. 
Additionally, it is thought that patients who respond to such 
diuretic treatment often have better physiological reserve in 
their kidneys and will exhibit a reduction in their SCr quicker than 
those who don’t respond to loop diuretics.
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Inotropic agents can be used to improve renal functions in 
low cardiac output states. Unlike other inotropes, levosimendan 
is a non-catecholamine calcium sensitizer which has stabilising 
effect on troponin C to enhance cardiac contractility without 
increasing myocardial oxygen consumption, leading to 
haemodynamic stability of myocardium[61]. It has been shown 
to have beneficial effect in decreasing low cardiac output 
syndrome and mortality after cardiac surgery[62]. An up-to-date 
meta-analysis of 12 RCTs conducted by Ng et al. reported that 
patients with preoperative low left ventricular ejection fraction 
(≤ 50%) who received levosimendan had significantly lesser 
risk of AKI than those treated with placebo[63]. Despite being 
reported as the most efficacious inodilator, levosimendan is, 
nonetheless, expensive and may not be available or ready to use 
in every centre.
Apart from the hematopoietic effect, studies have 
supported the idea that exogenous erythropoietin (EPO) exerts 
renoprotective effects against ischemia-reperfusion injury, 
suppressing oxidative stress and inflammation and attenuating 
apoptosis[64]. However, recent studies show conflicting findings. 
NMA conducted by Chen et al. showed that high-dose EPO (400-
500 IU/kg) did not have effect on AKI prevention after cardiac 
surgery but low-dose EPO (200-300 IU/kg) might be effective[57]. 
Another recent meta-analysis conducted by Penny-Dimri et al.[65] 
found out a direct correlation between pre-anaesthetic EPO 
administration with reduced incidence of AKI postoperatively, 
but the authors claimed that the study yielded small sample size 
and demonstrated significant heterogeneity. Therefore, future 
larger studies are needed to ascertain the optimal dose and the 
timing of administration of EPO.
N-acetylcysteine (NAC) is a thiol compound which possesses 
antioxidant property that can scavenge ROS. Therefore, NAC 
can potentially ameliorate ischemia-reperfusion injury and 
inflammation, which are the main pathophysiology in CPB. 
NAC has also been demonstrated to decrease the risk of CIN 
in humans[65]. Although NAC is inexpensive, there is no solid 
evidence supporting the prophylactic administration of NAC in 
reducing incidence of AKI after cardiac surgery. One recent meta-
analysis concluded that NAC was not effective in preventing 
CSA-AKI occurrence and improving SCr level or reducing length 
of hospital stay and mortality rate compared with placebo[66].
KDIGO recommends intravenous saline or sodium 
bicarbonate for those who are at risk of CI-AKI[20]. However, a 
comprehensive systematic review which included 3563 patients 
found no clear evidence of benefits associated with the use of 
sodium bicarbonate[67]. While the pilot study of Hasse et al.[68] 
found out that sodium bicarbonate infusion could significantly 
reduce the risk of AKI in patients undergoing cardiac surgery 
with CPB via urinary alkalization, recent meta-analyses failed to 
show the association of sodium bicarbonate infusion in lowering 
incidence of AKI, with one of the studies showing the possibility 
of increased mortality[69].
Mannitol is an osmotic diuretic which is often added to CPB 
prime. Even though mannitol has been studied and used in the 
belief that it has renoprotective property in patients undergoing 
cardiac surgery, the evidence of benefit of mannitol in this setting 
remains controversial and contradictory[68,70]. In a prospective 
routinely in preventing AKI. Table 5 is a summary of the key studies 
about the pharmacological protection against development of 
AKI in cardiac surgery patients.
Dexmedetomidine, a highly selective central alpha2 
adrenoreceptor agonist, was found to reduce the incidence of AKI 
in several studies. Recently, Liu et al. conducted a meta-analysis 
of 10 RCTs, involving 1575 patients undergoing cardiac surgery, 
to compare the effect of dexmedetomidine with placebo and 
other drugs on the AKI risk and mortality[54]. They reported an 
association of dexmedetomidine in decreasing postoperative 
AKI risk, but no significant decrease in other parameters such 
as duration of mechanical ventilation and length of hospital 
or ICU stay. Balkanay et al. performed a triple-blinded RCT 
and demonstrated marked effects of dexmedetomidine on 
renoprotection and decreasing NGAL concentration after CABG 
under CPB in a dose-dependent pattern[55]. However, to date, the 
optimal dose of dexmedetomidine to improve renal function after 
cardiac surgery remains uncertain. On top of the lipid-lowering 
properties, statins have anti-inflammatory, antioxidant, and anti-
thrombotic properties, thus aiding in improving the endothelial 
function. All these properties proposed that statin is likely to be 
renoprotective. A retrospective study by Billings et al.[55] found out 
that early postoperative statin administration may play a role in 
preventing AKI. On the contrary, Lewicki et al.[56], who conducted 
a systematic review with 662 participants, led to a conclusion 
that empirical statin therapy did not improve renal function or 
mortality. Large high-quality RCTs are warranted to establish the 
safety and efficacy of statins to prevent AKI after cardiac surgery.
Renal vasodilators, such as fenoldopam, natriuretic peptide, 
and levosimendan, have been verified by the network meta-
analysis (NMA) performed by Chen et al.[57] for their effectiveness 
in increasing renal blood flow and reducing AKI risk after cardiac 
surgery. However, the current guideline from KDIGO expert 
committee does not include fenoldopam and natriuretic 
peptide[20].
Fenoldopam, a dopamine-1 receptor partial agonist, may 
have renoprotective function due to its vasodilatory and 
natriuretic effect in potentially reversing renal hypoperfusion. 
Ranucci et al.[58] performed a double-blind RCT including 80 
patients undergoing complex cardiac surgery. The authors 
found out that patients treated with fenoldopam had higher 
oxygen delivery during CPB, lower AKI risk, and major morbidity 
rates than the placebo group[57]. In contrast, one recent meta-
analysis in cardiac surgery and major surgery demonstrated the 
association of fenoldopam in reducing AKI significantly, but with 
no impact on the requirement of RRT, mortality, and length of 
ICU or hospital stays[58].
Atrial natriuretic peptide (ANP) and brain natriuretic peptide 
(BNP) suppress the renin-angiotensin-aldosterone system and 
induces renal arterial vasodilation, which reduces renal ischemia-
reperfusion injury[59]. Sezai et al.[60] reported that prophylactic 
use of ANP during cardiac surgery with CPB can prevent the 
deterioration of renal function. A multicenter prospective RCT in 
Japan reported that low-dose ANP infusion had no protective 
effect on kidney, but the finding was underpowered by its small 
sample size[60]. In general, the overall quality of evidence of the 
drugs was weak and conflicting.
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CONCLUSION
CSA-AKI is a serious complication and can dramatically 
increase perioperative morbidity and mortality, even so, this 
condition can be prevented through different perioperative 
measures. Focused studies on identifying key predictive factors 
for such morbidity and monitoring the progress are crucial to 
improve outcomes in such high-risk cohort.
observational study, Bragadottir et al. reported that mannitol 
induces a renal vasodilation, which increases blood flow to the 
kidneys with balanced renal oxygenation and filtration fraction[70]. 
On the other hand, other studies found no differences between 
the mannitol group and the control cohort[7].
Usually, volatile anaesthetics are used in surgery for general 
anaesthesia to induce and maintain analgesia, hypnosis, 
amnesia, and create mild relaxation of muscle. Besides, an animal 
study conducted by Jia et al. proved that volatile anaesthetics 
confer protection against renal ischemia-reperfusion injury[71,72]. 
Cai et al. performed a meta-analysis of 10 RCTs involving 1600 
patients who underwent cardiac surgery[73]. Table 6 is a summary 
of their findings; the authors found out that administration of a 
volatile anaesthetic significantly reduced the incidence of post-
cardiovascular surgery AKI, as well as the incidence of prolonged 
stay in hospital/ICU, and slightly decreased mortality[73].
Table 6. Main findings from Cai et al.[74] study in relation to pharmacological protection of kidneys to prevent acute kidney injury 
















Dexmedetomidine Liu et al., 2018 10 1575 AKI 0.65 (0.45, 0.92) 0.02 0%
Statin Putzu et al., 2016 23 5102 AKI 1.26 (1.05, 1.52) 0.01 Not reported
Statin Lewicki et al., 2015 7 662 AKI RR 0.76 (0.46, 1.28) Not reported 0%
Fenoldopam Gillies et al., 2015 6 507 AKI 0.46 (0.27, 0.79) 0.004 0%
Fenoldopam Zangrillo et al., 2012 6 440 AKI 0.41 (0.23, 0.74) 0.003 0%
Levosimendan Ng et al., 2019 12 1867 AKI 0.61 (0.40, 0.92) 0.02 33%
Levosimendan Tena et al., 2018 14 2243 RRT RR 0.66 (0.47, 0.92) 0.015 0%
Erythropoietin Penny-Dimri et al., 2016 6 473 AKI 0.69 (0.35, 1.36) 0.28 64%
N-acetylcysteine Mei et al., 2017 10 1391 AKI 0.841 (0.691, 1.023) 0.116 39.4%
N-acetylcysteine Ho et al., 2009 10 1193 AKI 1.04 (0.45, 2.37) Not reported 3.3%
N-acetylcysteine Nigwekar et al., 2009 12 1324 AKI 0.89 (0.68, 1.15) 0.36 0%
Sodium bicarbonate Tie et al., 2014 5 1079 AKI 0.99 (0.78, 1.24) 0.911 56.1%
Sodium bicarbonate Bailey et al., 2015 3 877 * 1.11 (0.77, 1.60) 0.45 Not reported
Sodium bicarbonate Kim et al., 2015 5 1092 AKI 0.95 (0.74, 1.22) 0.71 59%
Sodium bicarbonate Zoungas et al., 2009 23 3563 CIN 0.62 (0.45, 0.86) Not reported 49.1%
Volatile anaesthetics Cai et al., 2014 10 1600 AKI 0.65 (0.43, 0.97) 0.04 0%
*Postoperative increase in serum creatinine concentration of greater than 25% or 0.5 mg/dL within the first five postoperative days.
CI=confidence interval; CIN=contrast-induced nephropathy; OR=odds ratio; RR=risk ratio; RRT=renal replacement therapy
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